Literature DB >> 24880154

Protection by inosine in a cellular model of Parkinson's disease.

S Cipriani1, R Bakshi2, M A Schwarzschild2.   

Abstract

Inosine (hypoxanthine 9-beta-D-ribofuranoside), a purine nucleoside with multiple intracellular roles, also serves as an extracellular modulatory signal. On neurons, it can produce anti-inflammatory and trophic effects that confer protection against toxic influences in vivo and in vitro. The protective effects of inosine treatment might also be mediated by its metabolite urate. Urate in fact possesses potent antioxidant properties and has been reported to be protective in preclinical Parkinson's disease (PD) studies and to be an inverse risk factor for both the development and progression of PD. In this study we assessed whether inosine might protect rodent MES 23.5 dopaminergic cell line from oxidative stress in a cellular model of PD, and whether its effects could be attributed to urate. MES 23.5 cells cultured alone or in presence of enriched murine astroglial cultures MES 23.5-astrocytes co-cultures were pretreated with inosine (0.1-100 μM) for 24 h before addition of the oxidative stress inducer H₂O₂ (200 μM). Twenty-four hours later, cell viability was quantified by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay or immunocytochemistry in pure and MES 23.5-astrocytes co-cultures, respectively. H₂O₂-toxic effect on dopaminergic cells was reduced when they were cultured with astrocytes, but not when they were cultured alone. Moreover, in MES 23.5-astrocytes co-cultures, indicators of free radical generation and oxidative damage, evaluated by nitrite (NO₂(-)) release and protein carbonyl content, respectively, were attenuated. Conditioned medium experiments indicated that the protective effect of inosine relies on the release of a protective factor from inosine-stimulated astrocytes. Purine levels were measured in the cellular extract and conditioned medium using high-performance liquid chromatography (HPLC) method. Urate concentration was not significantly increased by inosine treatment however there was a significant increase in levels of other purine metabolites, such as adenosine, hypoxanthine and xanthine. In particular, in MES 23.5-astrocytes co-cultures, inosine medium content was reduced by 99% and hypoxanthine increased by 127-fold. Taken together these data raise the possibility that inosine might have a protective effect in PD that is independent of any effects mediated through its metabolite urate.
Copyright © 2014 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HPLC; MES 23.5 cells; astrocytes; cell viability; oxidative stress; urate

Mesh:

Substances:

Year:  2014        PMID: 24880154      PMCID: PMC4120965          DOI: 10.1016/j.neuroscience.2014.05.038

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  45 in total

1.  [Protective effects of uric acid on nigrostriatal system injury induced by 6-hydroxydopamine in rats].

Authors:  Li-jun Wang; Wei-feng Luo; Heng-hui Wang; Gui-hua Ni; Yan Ye; Dan Li; Chun-feng Liu
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2010-05-18

2.  Identification of agents that reduce renal hypoxia-reoxygenation injury using cell-based screening: purine nucleosides are alternative energy sources in LLC-PK1 cells during hypoxia.

Authors:  Petra Szoleczky; Katalin Módis; Nóra Nagy; Zoltán Dóri Tóth; Douglas DeWitt; Csaba Szabó; Domokos Gero
Journal:  Arch Biochem Biophys       Date:  2011-11-11       Impact factor: 4.013

3.  Adenosine A2A receptors and uric acid mediate protective effects of inosine against TNBS-induced colitis in rats.

Authors:  Reza Rahimian; Gohar Fakhfouri; Ali Daneshmand; Hamed Mohammadi; Arash Bahremand; Mohammad Reza Rasouli; Kazem Mousavizadeh; Ahmad Reza Dehpour
Journal:  Eur J Pharmacol       Date:  2010-09-22       Impact factor: 4.432

4.  Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial.

Authors:  Richard E Gonsette; Christian Sindic; Marie B D'hooghe; Peter-Paul De Deyn; Robert Medaer; Alex Michotte; Pierrette Seeldrayers; Daniel Guillaume
Journal:  Mult Scler       Date:  2010-03-03       Impact factor: 6.312

5.  Cyclin-G-associated kinase modifies α-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study.

Authors:  Alexandra Dumitriu; Chris D Pacheco; Jemma B Wilk; Katherine E Strathearn; Jeanne C Latourelle; Stefano Goldwurm; Gianni Pezzoli; Jean-Christophe Rochet; Susan Lindquist; Richard H Myers
Journal:  Hum Mol Genet       Date:  2011-01-21       Impact factor: 6.150

6.  Inosine augments the effects of a Nogo receptor blocker and of environmental enrichment to restore skilled forelimb use after stroke.

Authors:  Laila Zai; Christina Ferrari; Carlie Dice; Sathish Subbaiah; Leif A Havton; Giovanni Coppola; Daniel Geschwind; Nina Irwin; Eric Huebner; Stephen M Strittmatter; Larry I Benowitz
Journal:  J Neurosci       Date:  2011-04-20       Impact factor: 6.167

7.  Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action.

Authors:  Ting-Ge Zhu; Xiao-Xia Wang; Wei-Feng Luo; Qi-Lin Zhang; Ting-Ting Huang; Xing-Shun Xu; Chun-Feng Liu
Journal:  Neurosci Lett       Date:  2011-11-06       Impact factor: 3.046

8.  Cytoprotective effects of adenosine and inosine in an in vitro model of acute tubular necrosis.

Authors:  Katalin Módis; Domokos Gero; Nóra Nagy; Petra Szoleczky; Zoltán Dóri Tóth; Csaba Szabó
Journal:  Br J Pharmacol       Date:  2009-11       Impact factor: 8.739

9.  Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.

Authors:  Michael A Schwarzschild; Alberto Ascherio; M Flint Beal; Merit E Cudkowicz; Gary C Curhan; Joshua M Hare; D Craig Hooper; Karl D Kieburtz; Eric A Macklin; David Oakes; Alice Rudolph; Ira Shoulson; Marsha K Tennis; Alberto J Espay; Maureen Gartner; Albert Hung; Grace Bwala; Richard Lenehan; Elmyra Encarnacion; Melissa Ainslie; Richard Castillo; Daniel Togasaki; Gina Barles; Joseph H Friedman; Lisa Niles; Julie H Carter; Megan Murray; Christopher G Goetz; Jeana Jaglin; Anwar Ahmed; David S Russell; Candace Cotto; John L Goudreau; Doozie Russell; Sotirios Andreas Parashos; Patricia Ede; Marie H Saint-Hilaire; Cathi-Ann Thomas; Raymond James; Mark A Stacy; Julia Johnson; Lisa Gauger; J Antonelle de Marcaida; Sheila Thurlow; Stuart H Isaacson; Lisbeth Carvajal; Jayaraman Rao; Maureen Cook; Charlise Hope-Porche; Lauren McClurg; Daniela L Grasso; Robert Logan; Constance Orme; Tori Ross; Alicia F D Brocht; Radu Constantinescu; Saloni Sharma; Charles Venuto; Joseph Weber; Ken Eaton
Journal:  JAMA Neurol       Date:  2014-02       Impact factor: 18.302

10.  Modulation of serum uric acid levels by inosine in patients with multiple sclerosis does not affect blood pressure.

Authors:  S Spitsin; C E Markowitz; V Zimmerman; H Koprowski; D C Hooper
Journal:  J Hum Hypertens       Date:  2009-10-29       Impact factor: 3.012

View more
  11 in total

1.  Inosine enhances recovery of grasp following cortical injury to the primary motor cortex of the rhesus monkey.

Authors:  Tara L Moore; Monica A Pessina; Seth P Finklestein; Ronald J Killiany; Bethany Bowley; Larry Benowitz; Douglas L Rosene
Journal:  Restor Neurol Neurosci       Date:  2016-09-21       Impact factor: 2.406

Review 2.  Targeting urate to reduce oxidative stress in Parkinson disease.

Authors:  Grace F Crotty; Alberto Ascherio; Michael A Schwarzschild
Journal:  Exp Neurol       Date:  2017-06-13       Impact factor: 5.330

3.  Total glycosides of Paeony shows Neuroprotective effects against Semen Strychni-induced neurotoxicity by recovering secretion of hormones and improving brain energy metabolism.

Authors:  Chenzhi Hou; Ruowen Zhang; Kexia Zhang; Xiaohui Chen
Journal:  Metab Brain Dis       Date:  2017-08-29       Impact factor: 3.584

4.  Protective Effects of Inosine on Memory Consolidation in a Rat Model of Scopolamine-Induced Cognitive Impairment: Involvement of Cholinergic Signaling, Redox Status, and Ion Pump Activities.

Authors:  Fernanda Cardoso Teixeira; Bruna da Silveira de Mattos; Julia Eisenhardt de Mello; Juliane Cardoso; Luiza Spohr; Karina Pereira Luduvico; Mayara Sandrielly Pereira Soares; Fabiano Barbosa Carvalho; Jessie Martins Gutierres; Anelize de Oliveira Campello Felix; Francieli Moro Stefanello; Roselia Maria Spanevello
Journal:  Neurochem Res       Date:  2021-10-08       Impact factor: 3.996

Review 5.  Purine nucleoside phosphorylase as a target to treat age-associated lower urinary tract dysfunction.

Authors:  Lori A Birder; Edwin K Jackson
Journal:  Nat Rev Urol       Date:  2022-09-07       Impact factor: 16.430

6.  Signaling pathways underlying the antidepressant-like effect of inosine in mice.

Authors:  Filipe Marques Gonçalves; Vivian Binder Neis; Débora Kurrle Rieger; Mark William Lopes; Isabella A Heinrich; Ana Paula Costa; Ana Lúcia S Rodrigues; Manuella P Kaster; Rodrigo Bainy Leal
Journal:  Purinergic Signal       Date:  2016-12-13       Impact factor: 3.765

7.  Serum urate at trial entry and ALS progression in EMPOWER.

Authors:  ÉIlis J O'Reilly; Dawei Liu; Donald R Johns; Merit E Cudkowicz; Sabrina Paganoni; Michael A Schwarzschild; Melanie Leitner; Alberto Ascherio
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-09-28       Impact factor: 4.092

Review 8.  Purines: forgotten mediators in traumatic brain injury.

Authors:  Edwin K Jackson; Detlev Boison; Michael A Schwarzschild; Patrick M Kochanek
Journal:  J Neurochem       Date:  2016-02-25       Impact factor: 5.372

9.  Inosine improves cognitive function and decreases aging-induced oxidative stress and neuroinflammation in aged female rats.

Authors:  Poonam Ruhal; Dinesh Dhingra
Journal:  Inflammopharmacology       Date:  2018-04-04       Impact factor: 4.473

Review 10.  Evidence for Oxidative Pathways in the Pathogenesis of PD: Are Antioxidants Candidate Drugs to Ameliorate Disease Progression?

Authors:  Alexander Leathem; Tamara Ortiz-Cerda; Joanne M Dennis; Paul K Witting
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.